Naturally Processed HLA Class II Peptides Reveal Highly Conserved Immunogenic Flanking Region Sequence Preferences That Reflect Antigen Processing Rather Than Peptide-MHC Interactions
The DOI matches its Crossref record.
Abstract
MHC class II heterodimers bind peptides 12–20 aa in length. The peptide flanking residues (PFRs) of these ligands extend from a central binding core consisting of nine amino acids. Increasing evidence suggests that the PFRs can alter the immunogenicity of T cell epitopes. We have previously noted that eluted peptide pool sequence data derived from an MHC class II Ag reflect patterns of enrichment not only in the core binding region but also in the PFRs. We sought to distinguish whether these enrichments reflect cellular processes or direct MHC-peptide interactions. Using the multiple sclerosis-associated allele HLA-DR2, pool sequence data from naturally processed ligands were compared with the patterns of enrichment obtained by binding semicombinatorial peptide libraries to empty HLA-DR2 molecules. Naturally processed ligands revealed patterns of enrichment reflecting both the binding motif of HLA-DR2 (position (P)1, aliphatic; P4, bulky hydrophobic; and P6, polar) as well as the nonbound flanking regions, including acidic residues at the N terminus and basic residues at the C terminus. These PFR enrichments were independent of MHC-peptide interactions. Further studies revealed similar patterns in nine other HLA alleles, with the C-terminal basic residues being as highly conserved as the previously described N-terminal prolines of MHC class II ligands. There is evidence that addition of C-terminal basic PFRs to known peptide epitopes is able to enhance both processing as well as T cell activation. Recognition of these allele-transcending patterns in the PFRs may prove useful in epitope identification and vaccine design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Wang, P., Sidney, J., Dow, C., Mothé, B., Sette, A., & Peters, B. (2008) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000048 · Cited by 844
Nielsen, M., & Lund, O. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-296 · Cited by 510
Reynisson, B., Barra, C., Kaabinejadian, S., Hildebrand, W. H., Peters, B., & Nielsen, M. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00874 · Cited by 445
Andreatta, M., Karosiene, E., Rasmussen, M., Stryhn, A., Buus, S., & Nielsen, M. (2015) · Immunogenetics · doi:10.1007/s00251-015-0873-y · Cited by 292
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
Jawa, V., Cousens, L. P., Awwad, M., Wakshull, E., Kropshofer, H., & De Groot, A. S. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.09.006 · Cited by 270
van Nierop, G. P., van Luijn, M. M., Michels, S. S., Melief, M.-J., Janssen, M., Langerak, A. W., Ouwendijk, W. J. D., Hintzen, R. Q., & Verjans, G. M. G. M. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1744-4 · Cited by 174
Ranking Peptide Binders by Affinity with AlphaFold**
Chang, L., & Perez, A. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202213362 · Cited by 100
Kumar, S., Singh, S. K., Wang, X., Rup, B., & Gill, D. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0414-9 · Cited by 85
Challenges targeting cancer neoantigens in 2021: a systematic literature review
Chen, I., Chen, M. Y., Goedegebuure, S. P., & Gillanders, W. E. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1935248 · Cited by 39
Kumar, S., Mitchell, M. A., Rup, B., & Singh, S. K. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23169 · Cited by 33
Hofer, L. S., Ramberger, M., Gredler, V., Pescoller, A. S., Rostásy, K., Sospedra, M., Hegen, H., Berger, T., Lutterotti, A., & Reindl, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01188 · Cited by 30
Metadata
- Authors
- Godkin, A. J., Smith, K. J., Willis, A., Tejada-Simon, M. V., Zhang, J., Elliott, T., & Hill, A. V. S.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-06-01
- Volume
- 166
- Issue
- 11
- Pages
- 6720-6727
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1535176600
- Cited by
- 125
- References
- 0
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.